ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 1, 2012
News
FDA Issues 483 to New England Compounding Center
By Angie Drakulich
New England Compounding Center gets 483 after linked fungal meningitis outbreak.
Third-Quarter 2012 Financial Reports Show Novartis and Merck Down
By Jennifer Markarian
Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
AET BioTech and BioXpress Therapeutics to Codevelop Adalimumab Biosimilar
By Adeline Siew, PhD
AET BioTech and BioXpress Therapeutics have entered into an agreement to codevelop a biosimilar version of Abbott's tumor necrosis factor inhibitor monoclonal antibody adalimumab.
Week of October 29, 2012: Novartis to Construct New Biotechnology Facility in Singapore; Patheon to Acquire Banner Pharmacaps; and More
Novartis to Construct New Biotechnology Facility in Singapore; Patheon to Acquire Banner Pharmacaps; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here